Enter your terms above and click the 'Search' button.

Showing articles 0 to 8 of 8 Filter Applied: safety (Click to remove) Adverse Events Associated with Disease-Modifying Drugs for Multiple Sclerosis Neurol 102:e208006, Ng, HS.,et al, 2024 Infection Risks Among Patients with Multiple Sclerosis Treated with Fingolimod, Natalizumab, Rituximab, and Injectable Therapies JAMA Neurol 77:184-191, Luna, G.,et al, 2020 Trial of Fingolimod Versus Interferon Beta-1a in Pediatric Multiple Sclerosis NEJM 379:1017-1027, Chitnis, T.,et al, 2018 Newer Agents in the Treatment of Multiple Sclerosis Neurologist 19:104-117, Pawate, S. & Bagnato F., 2015 Mechanisms of Fingolimods Efficacy and Adverse Effects in Multiple Sclerosis Ann Neurol 69:759-777, Cohen, J.A. & Chun, J., 2011 Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis NEJM 362:402-415, 456, Cohen,J.A.,et al, 2010 A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis NEJM 362:387-401, 456, Kappos, L.,et al, 2010 Oral Fingolimod (FTY720) in Multiple Sclerosis: Two-Year Results of a Phase II Extension Study Neurol 72:73-79, OConnor,P.,et al, 2009 Showing articles 0 to 8 of 8